Filing Flows › bioAffinity Technologies (BIAF) › Q2 2026 › vs Q2 2025
bioAffinity Technologies (BIAF) Q2 2026 vs Q2 2025 (year over year)
bioAffinity Technologies's revenue rose $241K (+19%) from $1.3M in Q2 2025 to $1.5M in Q2 2026. The biggest changes: Laboratory Services +$242K (+19%); Other Revenues −$1K (-58%).
bioAffinity Technologies, Q2 2026: revenue $1.5M (+19% year over year), operating margin -220.8%, net loss $3.4M, operating cash flow −$3.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Health Care, Patient Service | $1.2M | $942K | $302K | +32% |
| Histology Service Fees | $248K | $309K | −$60K | -20% |
| Medical Director Fees | $18K | $17K | $235 | +1% |
| Laboratory Services | $1.5M | $1.3M | $242K | +19% |
| Other Revenues | $1K | $2K | −$1K | -58% |
| Revenue | $1.5M | $1.3M | $241K | +19% |
| Net loss | $3.4M | $4.1M | −$695K | -17% |
| Costs & expenses | $4.9M | $5.3M | −$454K | -9% |
| Operating costs | $4.8M | $3.8M | $1.1M | +28% |
| Interest & other, net | $31K | $1.5M | −$1.5M | -98% |
| Research & development | $362K | $311K | $50K | +16% |
| SG&A | $2.9M | $2.2M | $644K | +29% |
| Other operating costs | $1.6M | $1.3M | $366K | +29% |
| Operating cash sources | $4.0M | $3.0M | $1.1M | +36% |
| Depreciation & amortization | $62K | $113K | −$52K | -46% |
| Share-based compensation | $785K | $212K | $573K | +271% |
| Cash used in operations | $3.2M | $2.6M | $554K | +21% |
| Net loss absorbed | $3.4M | $4.1M | −$695K | -17% |
| Working capital & other | $682K | −$1.1M | $1.8M | — |
Questions
How much did bioAffinity Technologies's revenue grow year over year in Q2 2026?
bioAffinity Technologies's revenue rose $241K (+19%) from $1.3M in Q2 2025 to $1.5M in Q2 2026.
What drove bioAffinity Technologies's revenue change in Q2 2026?
Laboratory Services +$242K (+19%); Other Revenues −$1K (-58%).